TFFP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TFFP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. TFF Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Sep. 2024 was $0.00 Mil. TFF Pharmaceuticals's average total debt for the quarter that ended in Sep. 2024 was $0.06 Mil. Therefore, TFF Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 was 0.00%.
The historical data trend for TFF Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TFF Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | - | - | - | - | - |
TFF Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, TFF Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where TFF Pharmaceuticals's Effective Interest Rate on Debt % falls into.
TFF Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2022 ) | + | Total Debt (A: Dec. 2023 )) | / count ) |
= | -1 * 0 | / | ( (0.191 | + | 0.116) | / 2 ) |
= | -1 * 0 | / | 0.1535 | |||
= | 0.00 % |
where
Total Debt (A: Dec. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.11 | + | 0.081 |
= | 0.191 |
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.032 | + | 0.084 |
= | 0.116 |
TFF Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Jun. 2024 ) | + | Total Debt (Q: Sep. 2024 )) | / count ) |
= | -1 * 0 | / | ( (0.074 | + | 0.052) | / 2 ) |
= | -1 * 0 | / | 0.063 | |||
= | 0.00 % |
where
Total Debt (Q: Jun. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 0.074 |
= | 0.074 |
Total Debt (Q: Sep. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 0.052 |
= | 0.052 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
TFF Pharmaceuticals (NAS:TFFP) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of TFF Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Carlson Capital L P | 10 percent owner | 2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201 |
Clint Duane Carlson | 10 percent owner | 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201 |
Zamaneh Mikhak | officer: Chief Medical Officer | 1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107 |
Robert S Mills | director | 8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812 |
Kirk Allen Coleman | officer: CFO, Secretary, and Treasurer | 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746 |
Stephen Rocamboli | director | C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019 |
Asgard Investment Corp. Ii | 10 percent owner | 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201 |
Double Black Diamond Offshore Ltd | 10 percent owner | CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205 |
Harlan F Weisman | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Brandi Roberts | director | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Fletcher Aaron G.l. | director | 40 GUEST STREET, BOSTON MA 02135 |
Randy H Thurman | director | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
Glenn R. Mattes | director, officer: President and CEO | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Malcolm Fairbairn | director | C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563 |
Lung Therapeutics, Inc. | 10 percent owner | P.O. BOX 150183, AUSTIN TX 78715 |
From GuruFocus
By Marketwired • 09-11-2024
By PRNewswire • 02-06-2025
By Marketwired • 06-24-2024
By Marketwired • 04-30-2024
By Marketwired • 05-23-2024
By GuruFocus News • 11-15-2024
By Marketwired • 08-14-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus News • 11-20-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.